当前，国内生物药企及CRO加速全球化布局，国际多中心临床试验（MRCT）已成为管线出海核心路径。但海外临床普遍存在启动周期长、受试者招募难、研发投入高、数据采信难等痛点，制约国际化进程。
凭借高效伦理审评体系、充足多元的初治受试者资源，新西兰已成为国内企业海外临床研发的优质优选地，具备试验启动快、成本可控、数据全球认可等显著优势。
为搭建中新临床研发对接通道，本次专场特邀新西兰顶尖临床机构CEO、CCO、CSO及核心PI，面向国内药企与CRO分享当地临床实操方案与合作路径，助力企业快速落地海外临床管线。
本次活动四大核心价值：
·极速启动，压缩研发周期
试验方案及研究者手册（IB）定稿后，2个月内即可完成首例受试者入组，大幅提速项目进度。
·高效招募，保障试验推进
依托丰富多元的初治受试者资源库，快速完成规模化入组，高效达成招募指标。
·数据通用，支撑全球申报
详解新西兰临床数据获得FDA、EMA官方采信的实操要点，强力赋能药品全球化上市。
·优化投入，实现降本增效
相较其他海外试验地区，项目执行成本可优化10%–60%，在保障试验质量的前提下最大化研发价值。
想要高效、高质量推进临床全球化布局，本次中新临床研发对接专场值得重点关注！
会议信息
时间：2026年11月20日（星期五）下午14:00‑16:00
地点：新西兰中心｜上海市黄浦区马当路 190 号
主办方
扫码注册参会
（免费注册，审核制）
About NZCR
NZCR is New Zealand’s leading clinical trials and medical research organisation.
With a focus on groundbreaking research and a commitment to participant safety, we have established ourselves as a trusted partner in the development of new medicines and medical treatments.
We are the leading early-phase clinical research provider in NZ. Following continued growth, we have acquired Optimal Clinical Trials to add considerable later-phase expertise to the NZCR Group.
As a physician-led organisation, we bring together over 35 years of research excellence and a track record of completing over 800 trials involving over 17,000 participants. We work closely with our sister company Optimal Clinical Trials to offer research across the entire lifecycle of a clinical trial.
With dosing units located in Auckland and Christchurch, plus two recruitment and outpatient sites located in Hamilton and Wellington we partner with global pharmaceutical, contract research organisations, and biotechnology companies to conduct complex clinical research in healthy participant and patient populations.